⌘K
Loading ticker…
As of 2026-08-24, Keros Therapeutics, Inc. Common Stock (KROS) has a 3-month relative strength percentile of 40 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 42. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.1%, relative volume 1.02×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
KROS appears in 1 ETF as of Jun 2026: PSC at 0.03% weight, $670K notional.
Held by 44 ETFs · $37M across latest filings · largest weight 0.38% (BBC).
Top 1 by value, from SEC N-PORT-P filings dated Jun 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| PSC | 0.03% | $670K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | KROS Jan avg: 5.30% median: 4.97% win: 50% σ: 30.76% n: 4 2022-04-12 → 2026-07-31 | KROS Feb avg: -2.70% median: -5.97% win: 25% σ: 18.02% n: 4 2022-04-12 → 2026-07-31 | KROS Mar avg: -12.98% median: -13.90% win: 0% σ: 9.62% n: 4 2022-04-12 → 2026-07-31 | KROS Apr avg: 3.29% median: 0.73% win: 60% σ: 23.16% n: 5 2022-04-12 → 2026-07-31 | KROS May avg: -9.21% median: -2.01% win: 40% σ: 17.62% n: 5 2022-04-12 → 2026-07-31 | KROS Jun avg: -9.47% median: -5.65% win: 0% σ: 7.15% n: 5 2022-04-12 → 2026-07-31 | KROS Jul avg: 6.30% median: 7.27% win: 80% σ: 8.09% n: 5 2022-04-12 → 2026-07-31 | KROS Aug avg: -2.32% median: -1.69% win: 50% σ: 12.59% n: 4 2022-04-12 → 2026-07-31 (current) | KROS Sep avg: 7.31% median: 5.19% win: 75% σ: 15.43% n: 4 2022-04-12 → 2026-07-31 | KROS Oct avg: 4.87% median: -1.92% win: 25% σ: 19.77% n: 4 2022-04-12 → 2026-07-31 | KROS Nov avg: 4.91% median: 2.90% win: 50% σ: 7.42% n: 4 2022-04-12 → 2026-07-31 | KROS Dec avg: -7.18% median: 6.41% win: 50% σ: 45.87% n: 4 2022-04-12 → 2026-07-31 |